产品
编 号：F355283
分子式：C21H28F3N3O7
分子量：491.46
分子式：C21H28F3N3O7
分子量：491.46
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
400
In-stock
1g
640
In-stock
结构图
CAS No: 42461-84-7
产品详情
生物活性：
Flunixin meglumine is a cyclooxygenase (COX) inhibitor with IC50 values of 0.55 and 3.24 μM for COX-1 and COX-2, respectively. Flunixin meglumine shows anti-inflammatory effects.
体内研究：
Flunixin meglumine (intravenous injection; 1.1 mg/kg; once) treatment inhibits the formation of exudate PGE2 and serum TXB2.Animal Model:Male sheep injected with Carrageenan
Dosage:1.1 mg/kg
Administration:Intravenous injection; 1.1 mg/kg; once
Result:Inhibited Carrageenan-induced exudate PGE2 formation (Emax, 100%, IC50, <0.4 nM) and serum TXB2 generation (Emax, 100%, IC50, 17 nM) for up to 32 h.
体外研究：
flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide (LPS)-induced activity of inducible nitric oxide synthase (iNOS) in RAW 264.7 murine macrophages.flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide-induced activation of nuclear factor kappa B (NfκB) in RAW 264.7 murine macrophages.
Flunixin meglumine is a cyclooxygenase (COX) inhibitor with IC50 values of 0.55 and 3.24 μM for COX-1 and COX-2, respectively. Flunixin meglumine shows anti-inflammatory effects.
体内研究：
Flunixin meglumine (intravenous injection; 1.1 mg/kg; once) treatment inhibits the formation of exudate PGE2 and serum TXB2.Animal Model:Male sheep injected with Carrageenan
Dosage:1.1 mg/kg
Administration:Intravenous injection; 1.1 mg/kg; once
Result:Inhibited Carrageenan-induced exudate PGE2 formation (Emax, 100%, IC50, <0.4 nM) and serum TXB2 generation (Emax, 100%, IC50, 17 nM) for up to 32 h.
体外研究：
flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide (LPS)-induced activity of inducible nitric oxide synthase (iNOS) in RAW 264.7 murine macrophages.flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide-induced activation of nuclear factor kappa B (NfκB) in RAW 264.7 murine macrophages.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备